Pharmacogenetics in multiple sclerosis: the long and winding road ahead of us

Yara Dadalti Fragoso

doi:10.1590/0004-282X20180115

Arquivos de Neuro-Psiquiatria, Table of Contents

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(10): 647-648
DOI: 10.1590/0004-282X20180115

Editorial

Pharmacogenetics in multiple sclerosis: the long and winding road ahead of us

Farmacognética na esclerose múltipla: a longa e tortuosa estrada à nossa frente

Authors

Yara Dadalti Fragoso

Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil.

Abstract

Full Text

References

References
1 Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol. 2010 Sep;63(9):960-9. https://doi.org/10.1016/j.jclinepi.2009.09.006
2 Werneck LC, Lorenzoni PJ, Kay CS, Scola RH. Multiple sclerosis: disease modifying therapy and the human leukocyte antigen. Arq Neuropsiquiatr. 2018;76(10):697-704. https://doi.org/10.1590/0004-282X20180103
3 Comabella M, Fernández-Arquero M, Río J, Guinea A, Fernández M, Cenit MC et al. HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2009 May;210(1-2):116-9. https://doi.org/10.1016/j.jneuroim.2009.01.012
4 Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics. 2007 Aug;17(8):657-66. https://doi.org/10.1097/FPC.0b013e3281299169
5 Fernández O, Fernández V, Mayorga C, Guerrero M, León A, Tamayo JA et al. HLA class II and response to interferon-beta in multiple sclerosis. Acta Neurol Scand. 2005 Dec;112(6):391-4. https://doi.org/10.1111/j.1600-0404.2005.00415.x
6 Samadzadeh S, Tabibian E, Sabokbar T, Shakoori A, Dehgolan SR, Armaki SA et al. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients. J Neurol Sci. 2015 May;352(1-2):37-40. https://doi.org/10.1016/j.jns.2015.03.004
7 Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB. Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity. Mult Scler Relat Disord. 2017 Apr;13:25-7. https://doi.org/10.1016/j.msard.2017.01.015
8 Kulakova O, Bashinskaya V, Kiselev I, Baulina N, Tsareva E, Nikolaev R et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci. Pharmacogenomics. 2017 Nov;18(17):1563-74. https://doi.org/10.2217/pgs-2017-0058
9 Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M et al. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Med. 2017 May;9(1):50. https://doi.org/10.1186/s13073-017-0436-y
10 Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S et al. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: insights from clinical research. Prog Neurobiol. 2017 May;152:114-30. https://doi.org/10.1016/j.pneurobio.2016.02.001
11 Tsareva E, Kulakova O, Boyko A, Favorova O. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs. Pharmacogenet Genomics. 2016 Mar;26(3):103-15. https://doi.org/10.1097/FPC.20180115201801150194